MicroTrend System for Hypoperfusion

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Captain James A. Lovell Federal Health Care Center, North Chicago, IL
Hypoperfusion
MicroTrend System - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The objective of this non-significant risk (NSR) study is to evaluate the safety and efficacy of the MicroTrend System by correlating POMCO2 data with relevant clinical metrics including arterial pressure and heart rate.

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 4-6 hours

4-6 hours
Correlation between POMCO2

Trial Safety

Trial Design

1 Treatment Group

MicroTrend System
1 of 1
Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: MicroTrend System · No Placebo Group · N/A

MicroTrend System
Device
Experimental Group · 1 Intervention: MicroTrend System · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4-6 hours
Closest Location: Captain James A. Lovell Federal Health Care Center · North Chicago, IL
2020First Recorded Clinical Trial
1 TrialsResearching Hypoperfusion
6 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are hospitalized in the critical care unit.
You are able to give informed consent.
You are willing and physically able to comply with the study protocol and procedures.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.